Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2018

21.11.2017 | Endocrine Tumors

Comparison of Recurrence Between Pancreatic and Duodenal Neuroendocrine Neoplasms After Curative Resection: A Single-Institution Analysis

verfasst von: Toshihiko Masui, MD, Asahi Sato, MD, Kenzo Nakano, MD, Yuichiro Uchida, MD, Akitada Yogo, MD, Takayuki Anazawa, MD, Kazuyuki Nagai, MD, Yoshiya Kawaguchi, MD, Kyoichi Takaori, MD, Shinji Uemoto, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The primary site of a neuroendocrine neoplasms (NEN) around the head of the pancreas is sometimes difficult to assess before resection, and the characteristics of the primary site around this region have not been elucidated for recurrence after curative resection. In this study, the clinicopathologic characteristics of pancreatic NEN (PanNEN) and duodenal NEN (DuNEN) were evaluated, and the risk factors as well as the recurrence types after resection were investigated.

Methods

Consecutively diagnosed NEN patients at the authors’ hospital from January 2000 to July 2016 were evaluated in this study. For 117 PanNEN patients and 31 non-ampullary DuNEN patients, R0 resection was achieved. The median follow-up period was 8.1 years.

Results

In this study, 27 PanNEN patients (23.1%) had recurrences, with a median disease-free survival (DFS) of 133 months, whereas 11 DuNEN patients (35.5%) had recurrences, with a median DFS of 156 months. The PanNEN patients tended to have primary recurrence in the liver (85.2%), followed by lymph nodes (11.1%). The independent risk factors for short DFS were lymph node metastasis at resection (p = 0.001) and microvascular invasion (p = 0.048). In contrast, the DuNEN patients were likely to have lymph node metastasis (81.8%). The independent risk factors for short DFS were lymph node metastasis at resection (p = 0.003) and large diameter (p = 0.013).

Conclusions

Most initial recurrences of PanNEN occurred in the liver, whereas those of DuNEN appeared in lymph nodes, suggesting that proper diagnosis of the primary site and appropriate imaging methods for surveillance after resection are necessary.
Literatur
1.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed
2.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.CrossRefPubMed Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.CrossRefPubMed
3.
Zurück zum Zitat Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed
4.
Zurück zum Zitat Jilesen AP, van Eijck CH, Busch OR, van Gulik TM, Gouma DJ, van Dijkum EJ. Postoperative outcomes of enucleation and standard resections in patients with a pancreatic neuroendocrine tumor. World J Surg. 2016;40:715–28.CrossRefPubMed Jilesen AP, van Eijck CH, Busch OR, van Gulik TM, Gouma DJ, van Dijkum EJ. Postoperative outcomes of enucleation and standard resections in patients with a pancreatic neuroendocrine tumor. World J Surg. 2016;40:715–28.CrossRefPubMed
5.
Zurück zum Zitat Iwasaki T, Nara S, Kishi Y, Esaki M, Shimada K, Hiraoka N. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single-center experience and systematic review of the literature. Langenbeck’s Arch Surg. 2016. Iwasaki T, Nara S, Kishi Y, Esaki M, Shimada K, Hiraoka N. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single-center experience and systematic review of the literature. Langenbeck’s Arch Surg. 2016.
6.
Zurück zum Zitat Untch BR, Bonner KP, Roggin KK, et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg. 2014;18:457–62; discussion 462–53. Untch BR, Bonner KP, Roggin KK, et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg. 2014;18:457–62; discussion 462–53.
7.
Zurück zum Zitat Tsutsumi K, Ohtsuka T, Fujino M, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepato-Biliary-Pancreatic Sci. 2014;21:418–25.CrossRef Tsutsumi K, Ohtsuka T, Fujino M, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepato-Biliary-Pancreatic Sci. 2014;21:418–25.CrossRef
8.
Zurück zum Zitat Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs update: secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174:R1–7.PubMed Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs update: secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174:R1–7.PubMed
9.
Zurück zum Zitat Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exper Med Biol. 2015;867:125–43.CrossRef Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exper Med Biol. 2015;867:125–43.CrossRef
10.
Zurück zum Zitat d’Herbomez M, Coppin L, Bauters C, Rouaix-Emery N, Carnaille B, Do Cao C. Biomarkers of neuroendocrine tumors. Ann Biol Clin. 2016;74:669–79. d’Herbomez M, Coppin L, Bauters C, Rouaix-Emery N, Carnaille B, Do Cao C. Biomarkers of neuroendocrine tumors. Ann Biol Clin. 2016;74:669–79.
11.
Zurück zum Zitat Modlin IM, Frilling A, Salem RR, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016;159:336–47.CrossRefPubMed Modlin IM, Frilling A, Salem RR, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016;159:336–47.CrossRefPubMed
12.
Zurück zum Zitat Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70–8.CrossRefPubMed Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70–8.CrossRefPubMed
13.
Zurück zum Zitat Scigliano S, Lebtahi R, Maire F, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocrine-Related Cancer. 2009;16:977–90.CrossRefPubMed Scigliano S, Lebtahi R, Maire F, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocrine-Related Cancer. 2009;16:977–90.CrossRefPubMed
14.
Zurück zum Zitat Casadei R, Ricci C, Pezzilli R, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology. 2010;10:33–8.CrossRefPubMed Casadei R, Ricci C, Pezzilli R, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology. 2010;10:33–8.CrossRefPubMed
15.
Zurück zum Zitat Yamamoto Y, Okamura Y, Uemura S, et al. Vascularity and tumor size are significant predictors for recurrence after resection of a pancreatic neuroendocrine tumor. Ann Surg Oncol. 2017. Yamamoto Y, Okamura Y, Uemura S, et al. Vascularity and tumor size are significant predictors for recurrence after resection of a pancreatic neuroendocrine tumor. Ann Surg Oncol. 2017.
16.
Zurück zum Zitat Ge W, Zhou D, Xu S, Wang W, Zheng S. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic nonfunctioning pancreatic neuroendocrine tumors. Int J Surg. 2017;39:127–34.CrossRefPubMed Ge W, Zhou D, Xu S, Wang W, Zheng S. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic nonfunctioning pancreatic neuroendocrine tumors. Int J Surg. 2017;39:127–34.CrossRefPubMed
17.
Zurück zum Zitat Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis, and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19:675–97.CrossRefPubMed Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis, and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19:675–97.CrossRefPubMed
18.
Zurück zum Zitat Hatta W, Koike T, Iijima K, et al. The risk factors for metastasis in non-ampullary duodenal neuroendocrine tumors measuring 20 mm or less in diameter. Digestion. 2017;95:201–9.CrossRefPubMed Hatta W, Koike T, Iijima K, et al. The risk factors for metastasis in non-ampullary duodenal neuroendocrine tumors measuring 20 mm or less in diameter. Digestion. 2017;95:201–9.CrossRefPubMed
19.
Zurück zum Zitat Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Archiv. 2016;468:277–87.CrossRefPubMed Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Archiv. 2016;468:277–87.CrossRefPubMed
Metadaten
Titel
Comparison of Recurrence Between Pancreatic and Duodenal Neuroendocrine Neoplasms After Curative Resection: A Single-Institution Analysis
verfasst von
Toshihiko Masui, MD
Asahi Sato, MD
Kenzo Nakano, MD
Yuichiro Uchida, MD
Akitada Yogo, MD
Takayuki Anazawa, MD
Kazuyuki Nagai, MD
Yoshiya Kawaguchi, MD
Kyoichi Takaori, MD
Shinji Uemoto, MD
Publikationsdatum
21.11.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6260-1

Weitere Artikel der Ausgabe 2/2018

Annals of Surgical Oncology 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.